# FDA Warning Letter: Aurobindo Pharmaceutical Limited
> 2022-01-25 · Center for Drug Evaluation and Research | CDER · `00e5230a89c3684b`
## Letter
- **Company:** Aurobindo Pharmaceutical Limited
- **Posted Date:** 2022-01-25
- **Letter Issue Date:** 2022-01-12
- **Issuing Office:** Center for Drug Evaluation and Research | CDER
## Subject
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
---
*Source: [FDA Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) · AI Analytics · CC0 1.0*